Development of a core outcome set for cutaneous squamous cell carcinoma trials: identification of core domains and outcomes
Authors
Reynolds, K. A.Schlessinger, D. I.
Yanes, A. F.
Godinez-Puig, V.
Chen, B. R.
Kurta, A. O.
Cotseones, J. K.
Chiren, S. G.
Iyengar, S.
Ibrahim, S. A.
Kang, B. Y.
Worley, B.
Behshad, R.
DeHoratius, D. M.
Denes, P.
Drucker, A. M.
Dzubow, L. M.
Etzkorn, J. R.
Harwood, C. A.
Kim, J. Y. S.
Lawrence, N.
Lee, E. H.
Lissner, G. S.
Marghoob, A. A.
Guminiski, A.
Matin, R. N.
Mattox, A. R.
Mittal, B. B.
Thomas, J. R.
Zhou, X. A.
Zloty, D.
Hughes, B. G. M.
Nottage, M. K.
Green, Adèle C
Testori, A. A. E.
Argenziano, G.
Longo, C.
Zalaudek, I.
Lebbe, C.
Malvehy, J.
Saiag, P.
Cernea, S. S.
Schmitt, J.
Kirkham, J. J.
Poon, E.
Sobanko, J. F.
Cartee, T. V.
Maher, I. A.
Alam, M.
Affiliation
Department of Dermatology, Northwestern University, Chicago, IL, USAIssue Date
2020
Metadata
Show full item recordAbstract
Background: The lack of uniformity in the outcomes reported in clinical studies of the treatment of cutaneous squamous cell carcinoma (cSCC) complicates efforts to compare treatment effectiveness across trials. Objectives: To develop a core outcome set (COS), a minimum set of agreed-upon outcomes to be measured in all clinical trials of a given disease or outcome, for the treatment of cSCC. Methods: One hundred and nine outcomes were identified via a systematic literature review and interviews with 28 stakeholders. After consolidation of this long list, 55 candidate outcomes were rated by 19 physician and 10 patient stakeholders, in two rounds of Delphi exercises. Outcomes scored 'critically important' (score of 7, 8 or 9) by ≥ 70% of patients and ≥ 70% of physicians were provisionally included. At the consensus meeting, after discussion and voting of 44 international experts and patients, the provisional list was reduced to a final core set, for which consensus was achieved among all meeting participants. Results: A core set of seven outcomes was finalized at the consensus meeting: (i) serious or persistent adverse events, (ii) patient-reported quality of life, (iii) complete response, (iv) partial response, (v) recurrence-free survival, (vi) progression-free survival and (vii) disease-specific survival. Conclusions: In order to increase the comparability of results across trials and to reduce selective reporting bias, cSCC researchers should consider reporting these core outcomes. Further work needs to be performed to identify the measures that should be reported for each of these outcomesCitation
Reynolds KA, Schlessinger DI, Yanes AF, Godinez-Puig V, Chen BR, Kurta AO, et al. Development of a core outcome set for cutaneous squamous cell carcinoma trials: identification of core domains and outcomes. Br J Dermatol. 2020.Journal
British Journal of DermatologyDOI
10.1111/bjd.19693PubMed ID
33236347Additional Links
https://dx.doi.org/10.1111/bjd.19693Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1111/bjd.19693
Scopus Count
Collections
Related articles
- Development of a core outcome set for clinical trials in squamous cell carcinoma: study protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey.
- Authors: Schlessinger DI, Iyengar S, Yanes AF, Chiren SG, Godinez-Puig V, Chen BR, Kurta AO, Schmitt J, Deckert S, Furlan KC, Poon E, Cartee TV, Maher IA, Alam M, Sobanko JF
- Issue date: 2017 Jul 12
- Core Outcome Set for Actinic Keratosis Clinical Trials.
- Authors: Reynolds KA, Schlessinger DI, Vasic J, Iyengar S, Qaseem Y, Behshad R, DeHoratius DM, Denes P, Drucker AM, Dzubow LM, Etzkorn JR, Harwood C, Kim JYS, Lee EH, Lissner GS, Marghoob AA, Matin RN, Mattox A, Mittal BB, Thomas JR, Zhou XA, Zloty D, Schmitt J, Kirkham J, Poon E, Sobanko JF, Cartee TV, Maher IA, Alam M
- Issue date: 2020 Mar 1
- Development of a core outcome set for basal cell carcinoma.
- Authors: Schlessinger DI, Reynolds KA, Dirr MA, Ibrahim SA, Yanes AF, Lazaroff JM, Godinez-Puig V, Chen BR, Kurta AO, Cotseones JK, Chiren SG, Furlan KC, Iyengar S, Behshad R, DeHoratius DM, Denes P, Drucker AM, Dzubow LM, Etzkorn JR, Harwood CA, Kim JYS, Lawrence N, Lee EH, Lissner GS, Marghoob AA, Matin RN, Mattox AR, Mittal BB, Thomas JR, Zhou XA, Zloty D, Schmitt J, Kirkham JJ, Armstrong AW, Basset-Seguin N, Billingsley EM, Bordeaux JS, Brewer J, Brown M, Brown M, Collins SAB, Fargnoli MC, De Azevedo SJ, Dummer R, Eggermont A, Goldman GD, Haedersdal M, Hale EK, Hanlon A, Harms KL, Huang CC, Hurst EA, In GK, Kelleners-Smeets N, Kheterpal M, Leshin B, Mcdonald M, Miller SJ, Miller A, Mostow EN, Trakatelli M, Nehal KS, Ratner D, Rogers H, Sarin KY, Soon SL, Stasko T, Storrs PA, Tagliaferri L, Vidimos AT, Wong SL, Yu SS, Zalaudek I, Zeitouni NC, Zitelli JA, Poon E, Sobanko JF, Cartee TV, Maher IA, Alam M
- Issue date: 2022 Sep
- Development of a core outcome set for clinical trials in basal cell carcinoma: study protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey.
- Authors: Schlessinger DI, Iyengar S, Yanes AF, Lazaroff JM, Godinez-Puig V, Chen BR, Kurta AO, Henley JK, Chiren SG, Furlan KC, Schmitt J, Deckert S, Poon E, Sobanko JF, Cartee TV, Alam M, Maher IA
- Issue date: 2017 Oct 23
- Core outcome research measures in anal cancer (CORMAC): protocol for systematic review, qualitative interviews and Delphi survey to develop a core outcome set in anal cancer.
- Authors: Fish R, Sanders C, Williamson PR, Renehan AG
- Issue date: 2017 Nov 22